Non-CYP metabolism. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Clofarabine is a purine nucleoside antimetabolite, phosphorylated in the target cell to cytotoxic clorarabine triphosphate.

Clofarabine is used in the treatment of children with therapy resistant acute lymphatic leukaemia, where no other treatment is expected to be effective. Administered as an intravenous infusion. Common adverse reactions of clofarabine that can be confused with an acute porphyric attack are nausea, vomiting, diarrhoea, and abdominal pain as well as agitation, irritability, tachycardia, ascending neuropathy and paraesthesias. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Eliminated via a combination of renal and non-renal excretion. 60 % of the dose is excreted unchanged in urine within 24 hours. Non-renal elimination is not elucidated but does not include CYP-metabolism. No data supporting capacity for CYP-induction or inhibition. Interaction with drugs that induce or inhibit cytochrome P-450 (CYP) isoenzymes has not been registered and is not expected.

No.